Loading...
You have changed your country from
to
. Please be aware that this will change the currency in the purchasing process.
Products:Cell Biology >> Cell Cycle >> Cell Cycle Inhibitors >> Other
Overview
Product name
CHFR peptide
Protein description
Synthetic peptide derived from within residues 450 - 550 of Human CHFR.(Note: the amino acid sequence is proprietary)This peptide was used as an immunogen for ab4184 - CHFR antibody.
Properties
Purity
70 - 90% by HPLC
Form
Liquid
Storage instructions
Shipped at 4°C. Upon delivery aliquot and store at -20°C or -80°C. Avoid repeated freeze / thaw cycles.
Storage buffer
Information available upon request.
Concentration
Concentration information loading...
Research areas
Cancer >> Cell cycle >> Cell cycle inhibitors >> Other
Epigenetics and Nuclear Signaling >> Cell cycle >> Cell Cycle Inhibitors >> Other
Cell Biology >> Cell Cycle >> Cell Cycle Inhibitors >> Other
Applications
Application notes
This peptide can be used with studies using ab4184.
Protein info
Function
E3 ubiquitin-protein ligase that functions in the antephase checkpoint by actively delaying passage into mitosis in response to microtubule poisons. Acts in early prophase before chromosome condensation, when the centrosome move apart from each other along the periphery of the nucleus. Probably involved in signaling the presence of mitotic stress caused by microtubule poisons by mediating the 'Lys-48'-linked ubiquitination of target proteins, leading to their degradation by the proteasome. Promotes the ubiquitination and subsequent degradation of AURKA and PLK1. Probably acts as a tumor suppressor, possibly by mediating the polyubiquitination of HDAC1, leading to its degradation. May also promote the formation of 'Lys-63'-linked polyubiquitin chains and functions with the specific ubiquitin-conjugating UBC13-MMS2 (UBE2N-UBE2V2) heterodimer. Substrates that are polyubiquitinated at 'Lys-63' are usually not targeted for degradation, but are rather involved in signaling cellular stress.
Tissue specificity
Ubiquitous.
Pathway
Protein modification; protein ubiquitination.
Sequence similarities
Belongs to the CHFR family.
Contains 1 FHA domain.
Contains 1 PBZ-type zinc finger.
Contains 1 RING-type zinc finger.
Developmental stage
Weakly expressed in G1 phase, and highly expressed during S phase.
Domain
The PBZ-type zinc finger (also named CYR) mediates non-covalent poly(ADP-ribose)-binding. Poly(ADP-ribose)-binding is dependent on the presence of zinc and is required for its function in antephase checkpoint.
The FHA domain plays a key role in the anti-proliferative properties of the protein and is involved in initiating a cell cycle arrest at G2/M. The FHA domain may be required to interact with phosphorylated proteins.
Post-translational
modifications
Poly-ADP-ribosylated. In addition to binding non covalently poly(ADP-ribose) via its PBZ-type zinc finger, the protein is also covalently poly-ADP-ribosylated by PARP1.
Autoubiquitinated; may regulate its cellular level.
Phosphorylated upon DNA damage, probably by ATM or ATR (By similarity). Phosphorylated by PKB. Phosphorylation may affect its E3 ligase activity.
Cellular localization
Nucleus > PML body.
Target information above from: UniProt accessionQ96EP1
The UniProt Consortium
The Universal Protein Resource (UniProt) in 2010
Nucleic Acids Res. 38:D142-D148 (2010).
References for CHFR peptide (ab24681)
ab24681 has not yet been referenced specifically in any publications.
Publishing research using ab24681? Please let us know so that we can cite the reference in this datasheet
Please note: All products are "FOR RESEARCH USE ONLY AND ARE NOT INTENDED FOR DIAGNOSTIC OR THERAPEUTIC USE"